Evotec SE (NASDAQ:EVO) is considered one of the best debt-free penny stocks to buy. Just-Evotec Biologics received a grant from the Gates Foundation to improve access to biotherapeutics. The grant is also aimed at reducing the cost of monoclonal antibodies for infectious disease prevention in low-income countries.

Evotec is set to benefit from Amgen’s Dark Blue Acquisition, potentially worth up to $840 million. The company holds a 20% equity stake in Dark Blue and will receive proceeds from the transaction. Evotec has been involved in the development of Dark Blue’s technology platform.

Evotec is a global life sciences company specializing in drug discovery and development using cutting-edge technology and AI. While EVO shows investment potential, there are other AI stocks with greater upside and less downside risk. Investors looking for undervalued AI stocks can explore other options for potential growth.

For more investment opportunities, check out the best blue-chip stocks for 2026 and the top metal stocks to buy right now. This article is originally published on Insider Monkey and does not disclose any affiliations.

Read more at Yahoo Finance: Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now?